Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most of the activities of transcription factors are mediated by protein-protein interaction or binding to DNA in a sequence-specific fashion, both of which are conventionally considered challenging targets for development of small-molecule inhibitors (2).”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [2]
In the citing paper
“Undruggable proteins, which possess flat active sites, often act through PPI networks, which are characterized by large, flat, and undefined interfaces between proteins. These networks have been considered undruggable biological processes for decades.309–311”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [310]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Nitric oxide synthases: structure, function and inhibition
ALDERTON, W. K., COOPER, C. E., & KNOWLES, R. G. (2001) · Biochemical Journal · doi:10.1042/bj3570593 · Cited by 4,110
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Ghrelin: Structure and Function
Kojima, M., & Kangawa, K. (2005) · Physiological Reviews · doi:10.1152/physrev.00012.2004 · Cited by 2,810
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Research works printed but not linked: 4
- Das, R. C. & Morrow, K. J. J. in Antibody Engineering Report (Drug and Market Development Publications, 2002).
- Gibson, C. et al. Nonpeptidic α(v)β(3) Integrin antagonist libraries: on-bead screening and mass spectrometric identification without tagging. Angew. Chem. Int. Ed. Engl. 40, 165–169 (2001). · doi:10.1002/1521-3773(20010105)40:1<165::aid-anie165>3.0.co;2-8
- Raimundo, B. C. et al. Discovery of small-molecule inhibitors of interleukin-2 using fragment assembly. J. Med. Chem. (in the press). References 56–59 (and 62 below) detail an interdisciplinary approach, integrating fragment-based discovery, medicinal chemistry, and structural biology, to discovering inhibitors of the IL-2/IL-2R interaction.
- Hajduk, P. J. et al. High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 42, 2315–2317 (1999). · DOI · Paper page
Cited by
Items 901–1,000 of 1,003
Intrinsically disordered proteins: structural and functional dynamics
Wallin, S. (2017) · Research and Reports in Biology · doi:10.2147/rrb.s57282 · Cited by 23
“There have been several recent examples of successful small molecule inhibition of protein–protein interactions that hold promise particularly for cancer, 83,84 and some compounds have been taken to clinical trials.”
Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology
Li, K. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127717 · Cited by 18
Duan, L., Dong, S., Huang, K., Cong, Y., Luo, S., & Zhang, J. Z. H. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d0cp04693k · Cited by 18
Identification of novel Interleukin-2 inhibitors through computational approaches
Halim, S. A., Abdalla, O. M., Mesaik, M. A., Wadood, A., Ul‐Haq, Z., & Kontoyianni, M. (2013) · Molecular Diversity · doi:10.1007/s11030-013-9431-4 · Cited by 18
3D structure and the drug-discovery process
Hubbard, R. E. (2005) · Molecular BioSystems · doi:10.1039/b514814f · Cited by 22
Reverse MAPPIT detects disruptors of protein-protein interactions in human cells
Lemmens, I. H., Lievens, S., Eyckerman, S., & Tavernier, J. H. (2006) · Nature Protocols · doi:10.1038/nprot.2006.14 · Cited by 18
“, by the discovery of so-called 'hotspots'), and as new assays have become available, protein-protein interactions have become valid drug targets (reviewed in ref”
BackgroundDeng, N., & Cieplak, P. (2009) · Physical Chemistry Chemical Physics · doi:10.1039/b820961h · Cited by 18
Rabiee, A., Ebrahim‐Habibi, A., Navidpour, L., Morshedi, D., Ghasemi, A., Sabbaghian, M., Nemati‐Lay, M., & Nemat‐Gorgani, M. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01197.x · Cited by 18
“interactions, the search for small molecules that would be able to target these areas has regained strength in recent years (8).”
BackgroundProtein Surface Mimetics: Understanding How Ruthenium Tris(Bipyridines) Interact with Proteins
Hewitt, S. H., Filby, M. H., Hayes, E., Kuhn, L. T., Kalverda, A. P., Webb, M. E., & Wilson, A. J. (2016) · ChemBioChem · doi:10.1002/cbic.201600552 · Cited by 19
Mining a Kröhnke Pyridine Library for Anti-Arenavirus Activity
Miranda, P. O., Cubitt, B., Jacob, N. T., Janda, K. D., & de la Torre, J. C. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00236 · Cited by 18
Rational Modulator Design By Exploitation of protein–protein Complex Structures
Wichapong, K., Poelman, H., Ercig, B., Hrdinová, J., Liu, X., Lutgens, E., & Nicolaes, G. A. F. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0433 · Cited by 19
Anti-inflammatory mechanism research of tanshinone II A by module-based network analysis
Zheng, S., Ren, Z., Zhang, Y., & Qiao, Y. (2014) · Bio-Medical Materials and Engineering · doi:10.3233/bme-141211 · Cited by 18
“Therefore, several properties of PPI such as allosteric sites and hotspots, have been incorporated into drug-design strategies [10,11].”
Gavrilyuk, J. I., Evindar, G., & Batey, R. A. (2006) · Journal of Combinatorial Chemistry · doi:10.1021/cc050090+ · Cited by 18
Design and synthesis of backbone cyclic phosphorylated peptides: The IκB model
Qvit, N., Hatzubai, A., Shalev, D. E., Friedler, A., Ben‐Neriah, Y., & Gilon, C. (2008) · Biopolymers · doi:10.1002/bip.21098 · Cited by 20
Reddy, P. T., Quevillon, S., Gan, Z., Forbes, N., Leek, D. M., & Arya, P. (2006) · Journal of Combinatorial Chemistry · doi:10.1021/cc0600573 · Cited by 18
Scaffold-hopping for molecular glues targeting the 14-3-3/ERα complex
Konstantinidou, M., Zingiridis, M., Pennings, M. A. M., Fragkiadakis, M., Virta, J. M., Revalde, J. L., Visser, E. J., Ottmann, C., Brunsveld, L., Neochoritis, C. G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61176-4 · Cited by 19
“PPIs were traditionally considered dif fi cult targets due to the lack of well-de fi ned pockets and the presence of large, hydrophobic surfaces 3 – 5 .”
Self-citationSpatom: a graph neural network for structure-based protein–protein interaction site prediction
Wu, H., Han, J., Zhang, S., Xin, G., Mou, C., & Liu, J. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad345 · Cited by 17
Shaw, B. F., Moustakas, D. T., Whitelegge, J. P., & Faull, K. F. (2010) · Advances in protein chemistry and structural biology · doi:10.1016/s1876-1623(10)79004-0 · Cited by 19
Synthesis of Hydrogen‐Bond Surrogate α‐Helices as Inhibitors of Protein‐Protein Interactions
Miller, S. E., Thomson, P. F., & Arora, P. S. (2014) · Current Protocols in Chemical Biology · doi:10.1002/9780470559277.ch130202 · Cited by 18
“COMMENTARY Background Information Design of small molecule inhibitors for PPIs is often difficult (Arkin and Wells, 2004; Raj et al., 2013; Wells and McClendon, 2007).”
BackgroundTreatment of cancer by using Nanoparticles as a Drug Delivery
Patel, D. J., Mistri, P. A., & Prajapati, J. (2012) · International Journal of Drug Development and Research · Cited by 19
Dwivedi, A. K., & Iyer, P. K. (2013) · Macromolecular Bioscience · doi:10.1002/mabi.201300107 · Cited by 18
Analysis of RNA–protein interactions by a microplate-based fluorescence anisotropy assay
Mao, C., Goolsby, K. M., Wang, S., Dodson, R. E., Ross, J., & Shapiro, D. J. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2005.12.010 · Cited by 17
Nilebäck, E., Westberg, F., Deinum, J., & Svedhem, S. (2010) · Analytical Chemistry · doi:10.1021/ac1016419 · Cited by 17
Niu, R., Zheng, Q., Zhang, J., & Zhang, H. (2013) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2013.10.005 · Cited by 17
A Chemical Biology Strategy to Analyze Rheostat-like Protein Kinase-Dependent Regulation
Kawashima, S. A., Takemoto, A., Nurse, P., & Kapoor, T. M. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.01.003 · Cited by 17
Transcriptional tools: Small molecules for modulating CBP KIX‐dependent transcriptional activators
Bates, C. A., Pomerantz, W. C. K., & Mapp, A. K. (2010) · Biopolymers · doi:10.1002/bip.21548 · Cited by 22
Role of protein flexibility in the discovery of new drugs
Fuentes, G., Dastidar, S. G., Madhumalar, A., & Verma, C. S. (2010) · Drug Development Research · doi:10.1002/ddr.20399 · Cited by 20
Martinell, M., Salvatella, X., Fernández‐Carneado, J., Gordo, S., Feliz, M., Menéndez, M., & Giralt, E. (2006) · ChemBioChem · doi:10.1002/cbic.200500555 · Cited by 21
Prével, C., Kurzawa, L., Van, T. N. N., & Morris, M. C. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.003 · Cited by 23
Wrapping mimicking in drug‐like small molecules disruptive of protein–protein interfaces
Accordino, S. R., Morini, M. A., Sierra, M. B., Fris, J. A. R., Appignanesi, G. A., & Fernández, A. (2012) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24069 · Cited by 18
Maaty, W. S. A., & Weis, D. D. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b11742 · Cited by 19
Ghosh, M., Sodhi, S. S., Sharma, N., Mongre, R. K., Kim, N., Singh, A. K., Lee, S., Kim, D. C., Kim, S. W., Lee, H., et al. (2016) · BMC Genetics · doi:10.1186/s12863-016-0341-1 · Cited by 21
“Elucidating the modulation of protein-protein associations is challenging, but is receiving increasing research attention [54].”
BackgroundZhou, Y., Asahara, H., Schneider, N., Dranchak, P. K., Inglese, J., & Chong, S. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502512g · Cited by 17
Sun, C., Zhu, L., Zhang, C., Song, C., Wang, C., Zhang, M., Xie, Y., & Schaefer, H. F. (2018) · Journal of Computational Chemistry · doi:10.1002/jcc.25165 · Cited by 17
Lund, B. A., Thomassen, A. M., Nesheim, B. H. B., Carlsen, T. J. O., Isaksson, J. M., Christopeit, T., & Leiros, H. S. (2018) · FEBS Journal · doi:10.1111/febs.14643 · Cited by 17
Design, Synthesis, and Conformational Analysis of Oligobenzanilides as Multifacial α-Helix Mimetics
Flack, T., Romain, C., White, A., Haycock, P., & Barnard, A. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b01115 · Cited by 17
Activity‐Directed Synthesis of Inhibitors of the p53/ h DM2 Protein–Protein Interaction
Green, A. I., Hóbor, F., Tinworth, C. P., Warriner, S. L., Wilson, A. J., & Nelson, A. S. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202002153 · Cited by 18
Small molecules as tools for functional assessment of deubiquitinating enzyme function
Magin, R. S., Liu, X., Felix, A., Bratt, A. S., Chan, W. C., & Buhrlage, S. J. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.021 · Cited by 20
Yuan, Z., Kumar, E. A., Kizhake, S., & Natarajan, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1016413 · Cited by 21
Network-Based Study Reveals Potential Infection Pathways of Hepatitis-C Leading to Various Diseases
Mukhopadhyay, A., & Maulik, U. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094029 · Cited by 18
“Targeting protein-protein interactions has relatively recently been established to be a promising alternative to the conventional approach to drug design [8,9].”
BackgroundNagasaka, K., Kawana, K., Osuga, Y., & Fujii, T. (2013) · BioMed Research International · doi:10.1155/2013/369712 · Cited by 24
“However, targeting protein interactions are clearly more difficult than those targets that naturally bind molecules [55, 56].”
BackgroundThe promiscuous protein binding ability of erythrosine B studied by metachromasy (metachromasia)
Ganesan, L., & Buchwald, P. (2013) · Journal of Molecular Recognition · doi:10.1002/jmr.2263 · Cited by 17
Qvit, N., & Kornfeld, O. S. (2016) · Journal of Visualized Experiments · doi:10.3791/53589 · Cited by 17
Kröhnke pyridines: Rapid and facile access to Mcl-1 inhibitors
Conlon, I. L., Eker, D. V., Abdelmalak, S., Murphy, W. A., Bashir, H., Sun, M. A., Chauhan, J., Varney, K. M., Godoy‐Ruiz, R., Wilder, P. T., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.03.050 · Cited by 18
Margolles‐Clark, E., Kenyon, N. S., Ricordi, C., & Buchwald, P. (2010) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.01014.x · Cited by 17
Discovery of highly potent TNFα inhibitors using virtual screen
Shen, Q., Chen, J., Wang, Q., Deng, X., Liu, Y., & Lai, L. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.091 · Cited by 21
Shurtleff, A. C., Nguyen, T. L., Kingery, D. A., & Bavari, S. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.714364 · Cited by 17
“However, recent research has demonstrated that a small area of the interacting surface may actually account for the high-affinity binding [171-173].”
BackgroundWang, X., Saludes, J. P., Zhao, T. X., Csakai, A., Fiorini, Z., Chavez, S. A., Li, J., Lee, G., Varga, K., & Yin, H. H. (2012) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2012.05.013 · Cited by 17
Applied Virtual Screening: Strategies, Recommendations, and Caveats
Stumpfe, D., & Bajorath, J. (2011) · Methods and principles in medicinal chemistry · doi:10.1002/9783527633326.ch11 · Cited by 20
Selected hybrid natural products as tubulin modulators
Dasari, B., Jimmidi, R., & Arya, P. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.062 · Cited by 16
A Modular Synthesis of Conformationally Preorganised Extended β‐Strand Peptidomimetics
Yamashita, T., Knipe, P. C., Busschaert, N., Thompson, S., & Hamilton, A. D. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201501366 · Cited by 16
Targeting Virus-host Interactions of HIV Replication
Weydert, C., Rijck, J. D., Christ, F., & Debyser, Z. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150901115106 · Cited by 17
Xu, J., Miao, H., Zou, L., Bui, B. T. S., Haupt, K., & Pan, G. (2021) · Angewandte Chemie · doi:10.1002/ange.202106657 · Cited by 16
Application of Nanopore Sensors for Biomolecular Interactions and Drug Discovery
Jeong, K., Kim, J., Dhanasekar, N. N., Lee, M., & Chi, S. (2022) · Chemistry - An Asian Journal · doi:10.1002/asia.202200679 · Cited by 18
Selected Approaches to Disrupting Protein–Protein Interactions within the MAPK/RAS Pathway
Harwood, S. J., Smith, C. R., Lawson, J. D., & Ketcham, J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087373 · Cited by 17
Aeluri, M., Gaddam, J., Trinath, D. V. K. S., Chandrasekar, G., Kitambi, S. S., & Arya, P. (2013) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201300408 · Cited by 16
Cala, O., Remy, M., Guillet, V., Merdes, A., Mourey, L., Milon, A., & Czaplicki, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063908 · Cited by 16
“Physiological or pathological processes are mainly controlled by protein–protein interactions (PPIs) [1,2], which constitute a promising but difficult pharmacological target in many diseases.”
BackgroundBonache, M. Á., Balsera, B., Mendez, B. L., Millet, Ó., Brancaccio, D., Gomez-Monterrey, I. M., Carotenuto, A., Pavone, L. M., Reille‐Seroussi, M., Gagey‐Eilstein, N., et al. (2014) · ACS Combinatorial Science · doi:10.1021/co500005x · Cited by 16
Rigidified Clicked Dimeric Ligands for Studying the Dynamics of the PDZ1‐2 Supramodule of PSD‐95
Eildal, J. N. N., Bach, A., Dogan, J., Ye, F., Zhang, M., Jemth, P., & Strømgaard, K. (2014) · ChemBioChem · doi:10.1002/cbic.201402547 · Cited by 16
Synthetic molecules: helping to unravel plant signal transduction
Xuan, W., Murphy, E., Beeckman, T., Audenaert, D., & Smet, I. D. (2013) · Journal of Chemical Biology · doi:10.1007/s12154-013-0091-8 · Cited by 16
“In addition, development of small molecules that can modulate protein– protein interactions remains a challenge even in human drug development, and heavily relies on biochemical and biophysical knowledge of the respective target interactions [3].”
BackgroundSmith, S. E. P., Bida, A. T., Davis, T. R., Sicotte, H., Patterson, S. E., Gil, D., & Schrum, A. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045722 · Cited by 17
“disruption is expected to occur only rarely due to the binding of a single small drug [7].”
BackgroundMolecular Targets of Alcohol Action
Gorini, G., Bell, R. L., & Mayfield, R. D. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385506-0.00007-7 · Cited by 16
“This approach has emerged as an important area in medication development (277, 278).”
Construction of a natural product library containing secondary metabolites produced by actinomycetes
Takagi, M., & Shin‐ya, K. (2012) · The Journal of Antibiotics · doi:10.1038/ja.2012.52 · Cited by 16
Tantos, Á., Kalmár, L., & Tompa, P. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1042866 · Cited by 17
“In fact, there are only about eight drugs on the market that target protein– protein interaction interfaces [89,90].”
BackgroundThe CBM signalosome: Potential therapeutic target for aggressive lymphoma?
Yang, C., David, L., Qiao, Q., Damko, E., & Wu, H. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.12.008 · Cited by 18
Fragment-Based Drug Design: Strategic Advances and Lessons Learned
Chen, H., Zhou, X., Gao, Y., Chen, H., & Zhou, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12319-4 · Cited by 20
Mapping of Protein-Protein Interactions: Web-Based Resources for Revealing Interactomes
Gemović, B., Šumonja, N., Davidović, R., Perović, V., & Veljković, N. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180214113704 · Cited by 18
Intrinsic disorder and flexibility in proteins: a challenge for structural biology and drug design
Zanotti, G. (2023) · Crystallography Reviews · doi:10.1080/0889311x.2023.2208518 · Cited by 18
“Moreover, a linear peptide could also mimic a three-dimensional epitope, if the latter has been identified on the 3D structure of the folded target [95].”
BackgroundDailing, A., Luchini, A., & Liotta, L. A. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1079487 · Cited by 16
“Such biologic diversity (especially for 3 or more protein partners) makes techniques such as high-throughput chemical screening, or structure-based discovery, even more challenging [6].”
BackgroundInfluentialNeurobiological Applications of Small Molecule Screening
Bauer, A. J., & Stockwell, B. R. (2008) · Chemical Reviews · doi:10.1021/cr0782372 · Cited by 16
Epitope-Guided Engineering of Monobody Binders for in Vivo Inhibition of Erk-2 Signaling
Mann, J. K., Wood, J. F., Stephan, A. F., Tzanakakis, E. S., Ferkey, D. M., & Park, S. (2012) · ACS Chemical Biology · doi:10.1021/cb300579e · Cited by 18
“of designing small molecule inhibitors (13), epitope specific protein binders are attractive”
de Aquino, R. A. N., Modolo, L. V., Alves, R. B., & de Fátima, Â. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob41762j · Cited by 23
Docking protein domains in contact space
Lise, S., Walker-Taylor, A., & Jones, D. T. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-310 · Cited by 15
“g rational drug design and protein engineering [8]).”
BackgroundMcShan, A. C., Anbanandam, A., Patnaik, S., & Guzman, R. N. D. (2016) · ChemMedChem · doi:10.1002/cmdc.201600065 · Cited by 17
Zhang, H., Deng, Z., Yang, L., Luo, H., Liu, S., Li, Y., Wei, Y., Peng, S., Zhu, L., Wang, L., et al. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.01.009 · Cited by 16
Xu, D. D., Si, Y., & Meroueh, S. O. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00181 · Cited by 16
Kumar, A., Kaur, H., JAIN, A. C., Nair, D. T., & Salunke, D. M. (2018) · Scientific Reports · doi:10.1038/s41598-017-18733-9 · Cited by 16
Bojadzic, D., Chen, J., Alcazar, O., & Buchwald, P. (2018) · Molecules · doi:10.3390/molecules23051153 · Cited by 16
Dr. PIAS 2.0: an update of a database of predicted druggable protein–protein interactions
Sugaya, N., Kanai, S., & Furuya, T. (2012) · Database · doi:10.1093/database/bas034 · Cited by 17
Transcription factors in the development and treatment of immune disorders
Drinan, S. D., Bass, J. I. F., & Bass, J. I. F. (2023) · Transcription · doi:10.1080/21541264.2023.2294623 · Cited by 17
“Small molecules are well-suited for drug treatment because they are generally cell-permeable, can often be delivered orally, and are cost-effective [161,162].”
Parallel Synthesis of An Oligomeric Imidazole-4,5-dicarboxamide Library
Xu, Z., DiCesare, J. C., & Baures, P. W. (2010) · Journal of Combinatorial Chemistry · doi:10.1021/cc1000105 · Cited by 15
Voclosporin as a Treatment for Noninfectious Uveitis
Schultz, C. L. (2013) · Ophthalmology and Eye Diseases · doi:10.4137/oed.s7995 · Cited by 15
Computational probing protein–protein interactions targeting small molecules
Wang, Y., Chen, S., Deng, N.-Y., & Wang, Y. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv528 · Cited by 15
Kim, J., Lee, W. S., Koo, J., Lee, J., & Park, S. B. (2013) · ACS Combinatorial Science · doi:10.1021/co400128a · Cited by 15
Expanding the Conformational Selection Paradigm in Protein-Ligand Docking
Kuzu, G., Keskin, Ö., Gürsoy, A., & Nussinov, R. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-465-0_5 · Cited by 15
Sekikaic Acid and Lobaric Acid Target a Dynamic Interface of the Coactivator CBP/p300
Majmudar, C. Y., Højfeldt, J. W., Arewång, C.-J., Pomerantz, W. C. K., Gagnon, J. K., Schultz, P. J., Cesa, L. C., Doss, C. H., Rowe, S. P., Vásquez, V., et al. (2012) · Angewandte Chemie · doi:10.1002/ange.201206815 · Cited by 15
Singh, N., & Villoutreix, B. O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214364 · Cited by 16
“Protein–protein interactions (PPIs) regulate diverse types of biological activities both in healthy and disease states [35].”
BackgroundProtein-Protein Interactions as New Targets for Ion Channel Drug Discovery.
Stoilova‐McPhie, S., Ali, S. R., & Laezza, F. (2013) · PubMed · Cited by 15
Sharma, U., Srivastava, S., Prakesch, M. A., Sharma, M., Leek, D. M., & Arya, P. (2006) · Journal of Combinatorial Chemistry · doi:10.1021/cc060056a · Cited by 15
Gesto, D., Cerqueira, N. M. F. S. A., Ramos, M. J., & Fernandes, P. A. (2014) · Journal of Molecular Modeling · doi:10.1007/s00894-014-2178-8 · Cited by 16
“, identify which residues contribute the most to the monomer:monomer association [14, 15].”
BackgroundYang, C., Chen, S., Zhou, M., Li, Y., Li, Y., Zhang, Z., Liu, Z., Ba, Q., Li, J., Wang, H., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201400058 · Cited by 15
Acerra, N., Kad, N. M., & Mason, J. M. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt021 · Cited by 17
“An attractive strategy is the use of small molecules that modulate Ab aggregation (see Arkin and Wells, 2004; Doig, 2007; Berg, 2008 and references therein) and peptide-based ‘b-sheet breakers’ (BSBs) (Ghanta et al., 1996; Soto et al., 1996, 1998; Tjernberg et al., 1996; Findeis et al., 1999;…”
BackgroundInteracting partners of FEN1 and its role in the development of anticancer therapeutics
Kathera, C., Zhang, J., Janardhan, A., Sun, H., Ali, W., Zhou, X., He, L., & Guo, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.15176 · Cited by 16
“Size, hydrophobic nature and adaptivity features of small molecules could actively adjust to bind a drug like molecule into the Protein-protein interaction [30].”
BackgroundNatural products used as a chemical library for protein–protein interaction targeted drug discovery
Jin, X., Lee, K., Kim, N. H., Kim, H. S., Yook, J. I., Choi, J., & No, K. T. (2017) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2017.10.015 · Cited by 17
Interactome Mapping Uncovers a General Role for Numb in Protein Kinase Regulation
Wei, R., Kaneko, T., Liu, X., Liu, H., Li, L., Voss, C., Liu, E. V., He, N., & Li, S. S. ‐. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra117.000114 · Cited by 18
“Protein-protein interactions (PPIs)(1) play a pivotal role in all essential cellular processes, and dysregulation of PPI may lead to diseases such as cancer (1).”
BackgroundRecent advances in computational studies of GPCR-G protein interactions
Wang, J., & Miao, Y. (2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2018.11.011 · Cited by 21
“PPIs have been targeted for developing small-molecule modulators as therapeutic drugs (Andreani & Guerois, 2014; Arkin & Wells, 2004).”
Targeting the cis ‐dimerization of LINGO ‐1 with low MW compounds affects its downstream signalling
Cobret, L., de Tauzia, M.-L., Ferent, J., Traiffort, É., Hénaoui, I. S., Godin, F., Kellenberger, E., Rognan, D., Pantel, J., Bénédetti, H., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12945 · Cited by 16
“Due to the relatively large surfaces that are typically involved in protein–protein pairing, attempts to modulate such interactions with drug-like, low MW compounds have historically been considered challenging (Arkin and Wells, 2004; Thompson et al., 2012).”
BackgroundThermal aggregation of a model allosteric protein in different conformational states
Sabbaghian, M., Ebrahim‐Habibi, A., & Nemat‐Gorgani, M. (2008) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2008.11.011 · Cited by 15
Lerner, M. G., Meagher, K. L., & Carlson, H. A. (2008) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-008-9231-6 · Cited by 18
Wang, X., Fiorini, Z., Smith, C., Zhang, Y., Li, J., Watkins, L. R., & Yin, H. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047703 · Cited by 15
“Significant progress has been made in the development of small molecule regulators of PPIs [29,30,31], however, the development of small molecular probes to interrogate protein transmembrane domains is still lagging behind [32,33,34,35].”
Background
Metadata
- Authors
- Arkin, M. R., & Wells, J. A.
- Affiliations
- Sunesis (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 301-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2167398093
- Cited by
- 1,705
- References
- 178
- Citations by year
- 2026: 52 · 2025: 48 · 2024: 39 · 2023: 51 · 2022: 46 · 2021: 61 · 2020: 54 · 2019: 71 · 2018: 73 · 2017: 61 · 2016: 99 · 2015: 101 · 2014: 126 · 2013: 110 · 2012: 110
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, small molecule inhibitors, drug discovery, binding pocket, therapeutic target, inhibitor characterization
- MeSH terms
- Animals, Binding Sites, Enzyme Inhibitors, Humans, Protein Binding, Proteins, Receptors, Cell Surface, Drug Design, Computational Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.